Dana McClintock

Dr. McClintock has served as Alladapt’s Chief Medical Officer since 2018. Prior to joining Alladapt, Dr. McClintock was Global Head of Innovation for Immunology, Infectious Disease and Ophthalmology at Genentech/Roche. Her responsibilities included accelerating use of emergent technologies and enabling novel approaches to clinical development with a focus on pediatrics. Prior to this role, Dr. McClintock, held roles of increasing responsibility at Genentech/Roche, including Global Head of Pipeline and Portfolio planning for Immunology, Infectious Disease and Ophthalmology as well as Interim Global Co-Head of Ophthalmology. Earlier in Dr. McClintock’s career, she was deeply involved in both immunology and ophthalmology clinical development across a range of phases, from IND-enabling work and early clinical trials through post-marketing commitments and medical affairs activities. Dr. McClintock was involved in key clinical development activities for omalizumab (Xolair) and ranibizumab (Lucentis) as well as other pipeline molecules.

Dr. McClintock received a BA in Chemistry from Duke University and an MD from the University of Virginia. Dr. McClintock completed her training in Internal Medicine and Pulmonary and Critical Care Medicine, both at the University of California, San Francisco.